Last updated: 2026-09-08 07:52:20. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Aptorum Group Limited (APM) operates in the -- sector and is listed on NASDAQ. The stock is currently priced at --, with a market capitalization of -- and a P/E ratio of --. Over the past 52 weeks, its price has ranged from -- to --. This page covers its latest market performance, valuation, price trends and company information.
-- | |
-- | |
-- | |
-- | |
-- | |
-- | |
-- | |
-- | |
-- | |
-- | |
-- | |
-- |
Aptorum Group Limited (APM) last closed at $-- as of --, -- from the previous close of $--.
During the latest regular trading session, APM traded between $-- and $--, with a volume of -- shares. The closing price was -- and --.
Over the past seven days, Aptorum Group Limited (APM) moved from $7.91 to $7.00, representing a decline of 11.52% ($0.91).
The stock traded between $6.00 and $8.33 during the period. The latest price is near the middle of the 7-day range, indicating strong downward.
The average daily volume was 11.47 thousand shares, up versus the previous seven-day period, indicating higher trading activity.
Aptorum Group Ltd is a clinical-stage biopharmaceutical company. It is engaged in the discovery, development, and commercialization of therapeutic assets to treat diseases with unmet medical needs, particularly in oncology (including orphan oncology indications) and infectious diseases. Aptorum's project pipeline includes SACT-1, a repurposed drug for the treatment of neuroblastoma, and ALS-4, a small molecule for the treatment of bacterial infections caused by Staphylococcus aureus, including but not limited to Methicillin-resistant Staphylococcus aureus (MRSA).
| Employees | 2 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Aptorum Group Limited (APM) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.